RT Journal Article
T1 Real-life use of ramucirumab in gastric cancer in Spain: the RAMIS study.
A1 Longo, Federico
A1 Jorge, Mónica
A1 Yaya, Ricardo
A1 Montes, Ana Fernández
A1 Lago, Nieves Martínez
A1 Brozos, Elena
A1 Aparicio, Jorge
A1 Quintero, Guillermo
A1 Ceballos, Eduardo
A1 Buxó, Elvira
A1 Lopez, Ana Maria
A1 Pellón, Maria Luz
A1 Molina, Raquel
A1 Diaz-Paniagua, Laura
A1 Cerdà, Paula
A1 Leiva, Pedro Lopez
A1 Carnicero, Alfonso Martín
A1 Cousillas, Antía
A1 Paris, Lorena
A1 García-Paredes, Beatriz
A1 Romero, Carlos
A1 Ortega, María
A1 Molero, Alberto
A1 la Torre, Sergio de
A1 Jen, Min-Hua
A1 Díaz-Cerezo, Silvia
K1 effectiveness
K1 gastric cancer/GEJ adenocarcinoma
K1 ramucirumab
K1 real-world data
K1 treatment patterns
AB Aims: To obtain real-world data on ramucirumab use and effectiveness for the treatment of advanced gastric cancer (AGC) or gastroesophageal junction adenocarcinoma (GEJ). Methods: Observational, retrospective study carried out in 20 Spanish hospitals, in patients who started ramucirumab treatment between December 2015 and December 2018. Descriptive analysis was conducted for patient characteristics, treatment patterns and effectiveness outcomes. Results: Three hundred seventeen patients were included (93.7% treated with ramucirumab-paclitaxel and 6.3% with ramucirumab); age 62.5 (11.3) years; 66.9% male. Median progression-free survival and overall survival were 3.9 months (95% CI: 3.4-4.3) and 7.4 (95% CI: 6.4-8.9) in combination regimen and 2.0 (1.1-2.8) and 4.3 (95% CI: 1.9-7.3) in monotherapy, respectively. Conclusion: The study findings were consistent with available real-world studies and randomized clinical trials.
YR 2021
FD 2021-02-16
LK http://hdl.handle.net/10668/17186
UL http://hdl.handle.net/10668/17186
LA en
DS RISalud
RD Apr 7, 2025